Upexi Revenue Increases 85% Year-Over-Year to $44.6 Million for Fiscal 2022
HENDERSON, Nev., Sept. 29, 2022 /PRNewswire/ -- Upexi, Inc. (NASDAQ: UPXI), a multi-faceted brand owner, today announced its financial results for the fiscal year ending June 30, 2022.
Fiscal 2022 Financial Highlights:
- Revenue totaled $44.6 million, an increase of 85% year-over-year.
- Pro forma, unaudited revenue for fiscal 2022 totaled $68 million (reconciliation below).
- Gross profit totaled $25.2 million, an increase of 112% year-over-year.
- Gross profit margin improved to 56% as compared to 49% in fiscal 2021.
- Adjusted EBITDA totaled $3.4 million, an increase of 6.7% year-over-year (reconciliation below).
- GAAP Net Loss totaled $2.1 million as compared to net income of $2.9 million in fiscal 2021, primarily due to non-cash expenses.
- Cash and cash equivalents totaled $7.2 million as of June 30, 2022.
Allan Marshall, Chief Executive Officer of Upexi, stated, "During the 2022 fiscal year we successfully executed on our business model to acquire leading, profitable, and data-rich brands to quickly integrate and scale through our technology-driven platform. As a result, we are pleased to have increased revenue, gross profit margin, and adjusted EBITDA year-over-year. We have had a strong start to the 2023 fiscal year with the acquisition of LuckyTail, a leading international, recession-resilient, pet-care brand. Following up on our recent successes, we expect to evaluate and close other accretive transactions throughout the upcoming year. We are well positioned through our recent successful acquisitions, strong cash flow, and the ability to use our equity as currency to execute our core strategy of aggregating leading brands to grow the company and build value for our shareholders."
Operational Highlights for Fiscal 2022:
- August 1, 2021: Completed an asset purchase agreement with the members of VitaMedica Corporation, a leading online seller of supplements for surgery, recovery, skin, beauty, health, and wellness.
- October 1, 2021: Completed an equity interest purchase agreement, to acquire Interactive Offers, LLC, a SaaS, programmatic advertising company that has operated successfully in the fintech space for numerous years, with recent expansion into eCommerce to boost platform profits and growth.
- April 1, 2022: Completed a securities purchase agreement to acquire majority ownership of Cygnet Online, LLC, a well-established secondary market seller on Amazon with over 1,200 SKUs of branded OTC products and supplements in health, wellness, and beauty verticals.
- May 2022: Launched the Cure Mushrooms brand in the U.S., an organic medicinal mushroom extract nutraceutical.
Operational Highlights Subsequent to Fiscal 2022 Full Year
- August 12, 2022: Completed an asset purchase agreement to acquire substantially all of the assets of LuckyTail, an international pet care brand with strong presence on Amazon and its eCommerce store, offering grooming and nutritional products.
Financial Highlights for Fiscal 2022
Revenue totaled $44.6 million, an increase of $20.5 million or 85% for the fiscal year ended June 30, 2022, compared with the fiscal year ended June 30, 2021. Approximately $15 million or 73% of the increase was related to the acquisition of VitaMedica, Interactive and Cygnet and $5.5 million or 23% was related to the core business compared to the prior year period. The core business increase was related to increased manufacturing and the Company's own brands increase in direct to consumer sales.
Cost of revenue totaled $19.4 million, an increase of $7.2 million or 59% compared with the prior year. Approximately $6.8 million was related to the acquisition of VitaMedica, Interactive and Cygnet and $372,063 was related to the core business. Gross profit margin improved by 7% to 56%, compared to the prior year gross profit margin of 49%. The gross profit of the core business improved 9% to 58%, compared to the prior year. The gross margin improvement for the core business was primarily related to the consolidation of manufacturing, additional equipment purchased during the year, efficiency improvements in the manufacturing process and an increase in direct-to-consumer sales. Management expects to continue to improve gross margins as the Company consolidates acquisitions and controls direct costs.
Operating expenses totaled $27.9 million, an increase of $17.4 million or 166% compared with the prior fiscal year. Approximately $7.8 million was related to the sales, marketing and general administrative expenses of the acquisition of VitaMedica, Interactive and Cygnet. The core business sales and marketing increased by $2.3 million due to the increased spending on marketing of direct-to-consumer products and the growth of the sales and marketing team to support the current and expected future sales and product growth. The core business general and administrative expenses increased $2.8 million due to increased infrastructure, acquisition costs and employee related costs. The core business, non-cash expenses of share-based compensation, amortization and depreciation, increased $4.4 million. The Company's management is continuing to control operating expenses while also implementing management growth strategies.
Adjusted EBITDA for the fiscal year ended June 30, 2022 totaled $3.4 million, an increase of 6.7% as compared to $3.2 million for the fiscal year ended June 30, 2021.
The Company had a net loss of $2,046,030 compared to net income of $2,978,948 for the prior year. The change in net income primarily related to the $745,042 change of income tax benefit compared to the prior year and a $4,423,588 increase in non-cash expenses.
The Company writes-off the value of inventory deemed excessive or obsolete. The Company wrote off $1,044,607 and $375,000 of inventory during the year ended June 30, 2022, and 2021, respectively.
The Company has cash and cash equivalents of $7.2 million and stockholders' equity of $28.8 million as of June 30, 2022. As of September 26, 2022 there were 16,713,345 shares of common stock outstanding.
Consolidated Pro Forma Unaudited Financial Statements
The following unaudited pro forma combined financial information is based on the historical financial statements of the Company, VitaMedica, Interactive and Cygnet after giving effect to the Company's acquisitions of the companies as if the acquisitions occurred on July 1, 2021.
The following unaudited pro forma information does not purport to present what the Company's actual results would have been had the acquisitions occurred on July 1, 2021, nor is the financial information indicative of the results of future operations. The following table represents the unaudited consolidated pro forma results of operations for the fiscal years ending June 30, 2022, as if the acquisition occurred on July 1, 2021. Operating expenses for the fiscal years ending June 30, 2022 have been increased for the amortization expense associated with the fair value adjustment of definite lived intangible assets of VitaMedica, Interactive and Cygnet by $1,767,350.
Pro Forma, Unaudited | Proforma | |||||||||||||||||||||||
Year ended June 30, 2022 | Upexi, Inc. | VitaMedica | Interactive | Cygnet | Adjustments | Proforma | ||||||||||||||||||
Net sales | $ | 44,584,996 | $ | 384,391 | $ | 416,700 | $ | 22,583,781 | $ | $ | 67,969,868 | |||||||||||||
Cost of sales | $ | 19,396,123 | $ | 93,509 | $ | - | $ | 19,117,296 | $ | $ | 38,606,928 | |||||||||||||
Operating expenses | $ | 27,841,203 | $ | 255,286 | $ | 795,507 | $ | 2,086,722 | $ | 1,767,350 | $ | 32,746,068 | ||||||||||||
Net income (loss) | $ | (2,046,030) | $ | 35,596 | $ | (378,807) | $ | 1,117,971 | $ | (1,767,350) | $ | (3,038,620) | ||||||||||||
Basic income (loss) per common share | $ | (0.13) | $ | 0.36 | $ | (0.68) | $ | 2.01 | $ | $ | (0.17) | |||||||||||||
Weighted average shares outstanding | 16,224,520 | 100,000 | 560,170 | 555,489 | 17,440,179 | |||||||||||||||||||
Revenue Guidance for Fiscal 2023
Management expects revenue to increase in the 2023 fiscal year through both organic growth of the core business, acquisitions completed during the 2022 fiscal year and additional strategic acquisitions that align with managements long-term growth strategies. For fiscal 2023, management estimates baseline annual revenue to be in the range of $72 to $82 million for the full fiscal year.
About Upexi, Inc.: Upexi is a multi-faceted brand owner with established brands in the health, wellness, pet, beauty and other growing markets. We operate in emerging industries with high growth trends and look to drive organic growth of our current brands. We focus on direct to consumer and Amazon brands that are scalable and have anticipated, high industry growth trends. Our goal is to continue to accumulate consumer data and build out a significant customer database across all industries we sell into. The growth of our current database has been key to the year over year gains in sales and profits. To drive additional growth, we have and will continue to acquire profitable Amazon and eCommerce businesses that can scale quickly and reduce costs through corporate synergies. We utilize our in-house, SaaS programmatic ad technology to help achieve a lower cost per acquisition and accumulate consumer data for increased cross-selling between our growing portfolio of brands.
FORWARD LOOKING STATEMENTS:
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with business strategy, potential acquisitions, revenue guidance, product development, integration and synergies of acquiring companies and personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Reconciliation of Non-GAAP Adjusted EBITDA to GAAP Net Income (Net Loss) | ||||||||
Year Ended June 30, | ||||||||
2022 | 2021 | |||||||
Net income (Net loss) GAAP | $ | (2,046,030) | $ | 2,978,948 | ||||
Income tax | (518,398) | (1,282,815) | ||||||
Interest expense, net | 215,300 | 530,449 | ||||||
Depreciation and amortization | 2,733,455 | 1,030,021 | ||||||
Stock compensation | 2,755,016 | 611,432 | ||||||
Stock issued for services | 576,774 | 127,500 | ||||||
Change in derivative liability | 3,293 | - | ||||||
Gain on lease settlement | - | (387,860) | ||||||
Gain on SBA PPP loan forgiveness | (300,995) | (403,277) | ||||||
Gain on sale of asset | (5,500) | (8,708) | ||||||
Non-GAAP adjusted EBITDA | $ | 3,412,915 | $ | 3,195,690 | ||||
Use of Non-GAAP Financial Measures
The Company discloses and uses the above-mentioned non-GAAP financial measures internally as a supplement to GAAP financial information to evaluate its operating performance, for financial planning purposes, to establish operational goals, for compensation plans, to measure debt service capability, for capital expenditure planning and to determine working capital needs and believes that these are useful financial measures also used by investors. Non-GAAP adjusted EBITDA is defined as GAAP net income or net loss before interest, taxes, depreciation and amortization (EBITDA) adjusted for the non-cash stock compensation and stock option expense, acquisition, integration & restructuring expenses, charges and gains or losses from extinguishment of debt and other non-cash items. Non-GAAP EBITDA and non-GAAP adjusted EBITDA are not terms defined by GAAP and, as a result, the Company's measure of non-GAAP EBITDA and non-GAAP adjusted EBITDA might not be comparable to similarly titled measures used by other companies. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position, or cash flow that either excludes or includes amounts that are not normally included in the most directly comparable measure calculated and presented in accordance with GAAP. The non-GAAP financial measures discussed above, however, should be considered in addition to, and not as a substitute for, or superior to net income or net loss as reported for GAAP on the Consolidated Statements of Operations, cash and cash flows on the Consolidated Statement of Cash Flows or other measures of financial performance prepared in accordance with GAAP, and as reflected on the Company's financial statements prepared in accordance with GAAP. These non-GAAP financial measures are not a substitute for or presented in lieu of financial measures provided by GAAP and all measures and disclosures of financial information pursuant to GAAP should be read to obtain a comprehensive and thorough understanding of the Company's financial results. The reconciliations of non-GAAP EBITDA and non-GAAP adjusted EBITDA to GAAP operating income (loss) and/or GAAP net income (net loss) referred to in the highlights or elsewhere are provided in the schedules that are a part of this document.
Company Contact
Andrew Norstrud, Chief Financial Officer
Email: [email protected]
Phone: (702) 332-5591
Investor Relations Contact
KCSA Strategic Communications
Valter Pinto or Jack Perkins
Email: [email protected]
Phone: (212) 896-1254
UPEXI, INC. | ||||||||
June 30, | June 30, | |||||||
2022 | 2021 | |||||||
ASSETS | ||||||||
Current assets | ||||||||
Cash | $ | 7,149,806 | $ | 14,534,211 | ||||
Accounts receivable, net of allowance for doubtful accounts of $57,500 and $45,000, respectively | 2,155,125 | 1,277,662 | ||||||
Inventory | 6,454,428 | 2,094,952 | ||||||
Deferred tax asset, current | 462,070 | - | ||||||
Prepaid expenses and other receivables | 840,193 | 386,258 | ||||||
Total current assets | 17,061,622 | 18,293,083 | ||||||
Property and equipment, net | 8,046,486 | 2,832,400 | ||||||
Intangible assets, net | 12,052,020 | 1,845,166 | ||||||
Goodwill | 8,301,206 | 2,413,813 | ||||||
Deferred tax asset | 2,002,759 | 1,403,591 | ||||||
Other assets | 100,372 | 49,068 | ||||||
Right-of-use asset | 926,570 | 417,443 | ||||||
Total other assets | 31,429,413 | 8,961,481 | ||||||
Total assets | $ | 48,491,035 | $ | 27,254,564 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 2,591,149 | $ | 1,604,723 | ||||
Accrued compensation | 556,547 | 1,020,936 | ||||||
Deferred revenue | 335,205 | 485,973 | ||||||
Accrued liabilities | 952,249 | 296,021 | ||||||
Acquisition payable | - | 1,764,876 | ||||||
Current portion of notes payable | 5,424,752 | 447,100 | ||||||
Current portion of operating lease payable | 267,846 | 199,532 | ||||||
Total current liabilities | 10,127,748 | 5,819,161 | ||||||
Notes payable, net of current portion | 8,876,132 | - | ||||||
Operating lease payable, net of current portion | 700,411 | 217,430 | ||||||
Total long-term liabilities | 9,576,543 | 217,430 | ||||||
Commitments and contingencies | - | - | ||||||
Stockholders' equity | ||||||||
Preferred stock, $0.001 par value, 100,000,000 shares authorized, and 500,000 and 500,000 shares issued and outstanding, respectively | 500 | 500 | ||||||
Common stock, $0.001 par value, 100,000,000 shares authorized, and 16,713,345 and 15,262,394 shares issued and outstanding, respectively | 16,713 | 15,262 | ||||||
Additional paid in capital | 34,985,597 | 25,372,247 | ||||||
Accumulated deficit | (6,270,886) | (4,170,036) | ||||||
Total stockholders' equity attributable to Upexi, Inc. | 28,731,924 | 21,217,973 | ||||||
Non-controlling interest in subsidiary | 54,820 | - | ||||||
Total stockholders' equity | 28,786,744 | 21,217,973 | ||||||
Total liabilities and stockholders' equity | $ | 48,491,035 | $ | 27,254,564 | ||||
UPEXI, INC. | ||||||||
Year Ended June 30, | ||||||||
2022 | 2021 | |||||||
Revenue | ||||||||
Revenue | $ | 44,584,996 | $ | 24,095,025 | ||||
Cost of Revenue | 19,396,123 | 12,196,123 | ||||||
Gross profit | 25,188,873 | 11,898,902 | ||||||
Operating expenses | ||||||||
Sales and marketing | 7,628,932 | 2,388,211 | ||||||
General and administrative expenses | 14,147,230 | 6,442,501 | ||||||
Share-based compensation | 3,331,586 | 611,432 | ||||||
Amortization of acquired intangible assets | 2,159,146 | 726,525 | ||||||
Depreciation | 574,309 | 303,496 | ||||||
27,841,203 | 10,472,165 | |||||||
(Loss) income from operations | (2,652,330) | 1,426,737 | ||||||
Other expense (income), net | ||||||||
Interest expense (income), net | 215,300 | 530,449 | ||||||
Gain on sale of assets | (5,500) | (8,708) | ||||||
Gain on SBA PPP loan forgiveness | (300,995) | (403,277) | ||||||
Change in derivative liability | 3,293 | - | ||||||
Settlement of cancelled lease | - | (387,860) | ||||||
Other (income) expense, net | (87,902) | (269,396) | ||||||
(Loss) income before income tax | (2,564,428) | 1,696,133 | ||||||
Income tax (expense) benefit | 518,398 | 1,282,815 | ||||||
Net (loss) income | (2,046,030) | 2,978,948 | ||||||
Net loss attributable to noncontrolling interest | (54,820) | - | ||||||
Deemed dividend related to the issuance of Series A Preferred Stock | - | (50,000) | ||||||
Net (loss) income attributable to Upexi, Inc. | $ | (2,100,850) | $ | 2,928,948 | ||||
Basic (loss) income per share | $ | (0.13) | $ | 0.25 | ||||
Diluted (loss) income per share | $ | (0.13) | $ | 0.21 | ||||
Weighted average shares outstanding | 16,224,520 | 11,930,378 | ||||||
Fully diluted weighted average shares outstanding | 16,224,520 | 14,257,934 | ||||||
UPEXI, INC. | ||||||||
Year Ended June 30, | ||||||||
2022 | 2021 | |||||||
Cash flows from operating activities | ||||||||
Net (loss) income | $ | (2,046,030) | $ | 2,978,948 | ||||
Adjustments to reconcile net (loss) income to net cash provided by | ||||||||
operating activities: | ||||||||
Depreciation and amortization | 2,733,455 | 1,030,021 | ||||||
Inventory write-offs | 1,044,607 | 375,000 | ||||||
Gain on settlement of cancelled lease | - | (387,860) | ||||||
Gain on change in deferred tax allowance | (1,061,238) | (1,282,815) | ||||||
Amortization of beneficial conversion feature on convertible notes | 342,813 | |||||||
Shares issued for services | - | 127,500 | ||||||
Bad debt expense | 131,968 | 78,185 | ||||||
Gain on sale of equipment | (5,500) | (8,708) | ||||||
Gain on forgiveness of SBA PPP loan | (300,995) | (403,277) | ||||||
Stock based compensation | 3,331,586 | 611,432 | ||||||
Changes in assets and liabilities, net of acquired amounts | ||||||||
Accounts receivable | (17,312) | (1,138,228) | ||||||
Inventory | (2,447,038) | (846,659) | ||||||
Prepaid expenses and other assets | 217,824 | (313,206) | ||||||
Accounts payable and accrued liabilities | (430,506) | 1,966,806 | ||||||
Accrued liabilities related to acquisition | - | (90,876) | ||||||
Deferred revenue | (629,153) | (99,770) | ||||||
Net cash provided by operating activities | 521,872 | 2,939,306 | ||||||
Cash flows from investing activities | ||||||||
Acquisition of Infusionz, Inc., net of cash acquired | - | 62,122 | ||||||
Acquisition of VitaMedica, Inc., net of cash acquired | (2,574,589) | - | ||||||
Acquisition of Interactive Offers, Inc., net of cash acquired | (1,854,193) | - | ||||||
Acquisition of Cygnet, Inc., net of cash acquired | (1,028,763) | - | ||||||
Proceeds from sale of property and equipment | 6,000 | 79,000 | ||||||
Acquisition of property and equipment | (6,154,476) | (1,422,129) | ||||||
Net cash used in investing activities | (11,606,021) | (1,281,007) | ||||||
Cash flows from financing activities | ||||||||
Proceeds from issuance of common stock | - | 10,950,315 | ||||||
Stock repurchase program | (1,975,888) | - | ||||||
Proceeds from issuance of preferred stock | - | 50,000 | ||||||
Proceeds from issuance of related party note payable | - | 750,000 | ||||||
Repayment of related party note payable | - | (750,000) | ||||||
Payment of note payable | (1,002,874) | (12,000) | ||||||
Proceeds from issuance of notes payable | 6,678,506 | 1,000,080 | ||||||
Net cash provided by financing activities | 3,699,744 | 11,988,395 | ||||||
Net (decrease) increase in cash | (7,384,405) | 13,646,694 | ||||||
Cash, beginning of period | 14,534,211 | 887,517 | ||||||
Cash, end of period | $ | 7,149,806 | $ | 14,534,211 | ||||
Supplemental cash flow disclosures | ||||||||
Interest paid | $ | 64,460 | $ | - | ||||
Income tax paid | $ | 656,000 | $ | - | ||||
Issuance of common stock for acquisition of Infusionz | $ | 1,764,876 | $ | 650,255 | ||||
Issuance of common stock for conversion of notes payable and accrued interest | $ | 482,000 | $ | 3,085,273 | ||||
Repayment of Infusionz LLC debt to Upexi, Inc. | $ | - | $ | 72,000 | ||||
Liabilities assumed from acquisition of Infusionz | $ | - | $ | (680,480) | ||||
Liabilities assumed from acquisition of VitaMedica | $ | (309,574) | ||||||
Issuance of stock for acquisition of Interactive | $ | 2,733,628 | ||||||
Issuance of stock for acquisition of Cygnet | $ | 2,965,756 | ||||||
Liabilities assumed from acquisition of Cygnet | $ | 9,472,438 | ||||||
Stock issued for construction services | $ | 140,700 | $ | - | ||||
SOURCE Upexi, Inc.
Share this article